 |
|
|
| |
Population Pharmacokinetic Analysis of Velpatasvir, a Pangenotypic
HCV NS5A Inhibitor,
in Healthy and Hepatitis C Virus-Infected Subjects
|
| |
| |
Reported by Jules Levin
17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, 8-10 June 2016, Washington, DC, USA
Brian Kirby,1 Erik Mogalian,1 Yuying Gao,2 Kavitha Bhasi,1 Anita Mathias1
1Gilead Sciences, Inc., Foster City, California, USA; 2Quantitative Solutions, Inc., Menlo Park, California
Sofosbuvir/velpatasvir - (06/07/16)
FDA PDUFA, expected approval for Sof/velpatasvir is this June 28 2016
High Efficacy of Sofosbuvir/Velpatasvir In HCV Genotypes 1-6 Infected Patients With Cirrhosis: Pooled Data From the ASTRAL 1, 2 and 3 Trials (12/14/15)
EASL: Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study - (04/18/16)
Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir and Velpatasvir (GS-5816) and HIV Antiretoviral Therapies - (12/08/15)
EASL:Drug-Drug Interaction Profile of Sofosbuvir/Velpatasvir Fixed-Dose Combination - (04/21/16)
CL, linear elimination clearance; GI, gastrointestinal compartment; ka, 1st-order absorption rate constant; k20, rate constant for linear elimination; k23, rate constant from central to peripheral compartment; k32, rate constant from peripheral to central compartment; Tlag, lag time; Q, distribution clearance; Vc, central volume; Vp, peripheral volume
|
| |
|
|
|
|
|
